Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia

Ball, Lynne M.; Bredius, Robbert G. M.; Lankester, Arjan; Schweizer, Joachim J.; Heuvel‐Eibrink, MM van den; Escher, H; Fibbe, Willem E.; Egeler, M.

doi:10.1038/sj.leu.2405013

Cited by 34 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, their ability to quell the immune system is so potent, it has been exploited to reduce the severity of graft vs. host disease (GvHD). [140][141][142] MSCs appear to modulate immune responses via differential influences they exert on the proliferative capacities of immune cells. For example, MSCs inhibit the proliferation and maturation of B-cells 74 as well as natural killer cells, [143][144][145] while exhibiting protective activities toward other cells, such as neutrophils.…”

Section: Mscs In Tumor Pathogenesismentioning

confidence: 99%

Mesenchymal stem cells in tumor development

Cuiffo¹,

Karnoub²

2012

Cell Adhesion & Migration

179

120

View full text Add to dashboard Cite

Section: Mscs In Tumor Pathogenesismentioning

confidence: 99%

Mesenchymal stem cells in tumor development

Cuiffo¹,

Karnoub²

2012

Cell Adhesion & Migration

179

120

View full text Add to dashboard Cite

“…MSCs have been demonstrated to interfere with dendritic cell differentiation, maturation and function [98][99][100][101] . Based on these properties, MSCs are being used in regenerative medicine, for the treatment of autoimmune diseases [102,103] , graft versus host disease [104][105][106][107][108][109] and the tropism of MSCs for human gliomas can also be exploited to therapeutic advantage [110] . These cells can be a new alternative in cancer studies; in fact, recently an inhibiting effect of the MSC on the proliferation of the tumor was described [111] .…”

Section: Immunotherapy and Anti-inflammatory Therapy In Cancermentioning

confidence: 99%

Inflammation and cancer

Eiró

Vizoso²

2012

WJGS

132

View full text Add to dashboard Cite

“…1 However, cells with MSC-like characteristics can also be generated from adipose tissue, 2,3 or other tissues such as fetal liver, lungs, spleen, 4,5 amniotic fluid, 6 cord blood, 7 cord, 8,9 placenta, 10,11 human endometrium, 12 and dental pulp. 13 MSC demonstrate an immunomodulatory role both in vitro [14][15][16][17] and in vivo, 18,19 and are, therefore, able to improve the symptoms of graft-versus-host disease, [20][21][22][23] autoimmune diseases, 24 and degenerative diseases of the locomotor system. 25 MSC can be generated either by a plastic adherence method, whereby the unknown progenitor cells adhere to plastic (referred to as PA-MSC), or by positive selection with antibodies against cell surface antigens expressed by MSC-progenitor cells.…”

Section: Introductionmentioning

confidence: 99%

CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties

Kuçi¹,

Kuçi²,

Kreyenberg³

et al. 2010

Haematologica

153

135

View full text Add to dashboard Cite

BackgroundIn vitro proliferative and differentiation potential of mesenchymal stromal cells generated from CD271 + bone marrow mononuclear cells (CD271-mesenchymal stromal cells) has been demonstrated in several earlier and recent reports. In the present study we focused, in addition to proliferative and differentiation potential, on in vitro and in vivo immunosuppressive and lymphohematopoietic engraftment-promoting potential of these mesenchymal stromal cells compared to bone marrow-derived mesenchymal stromal cells generated by plastic adherence (plastic adherence-mesenchymal stromal cells). Design and MethodsWe set up a series of experimental protocols in order to determine the phenotype of CD271-mesenchymal stromal cells, and their clonogenic, proliferative, differentiation and immunosuppressive potential. The potential of CD271-mesenchymal stromal cells to improve the engraftment of CD133 + hematopoietic stem cells at co-transplantation was evaluated in immunodeficient NOD/SCID-IL2Rg null mice. ResultsIn vitro studies demonstrated that CD271-mesenchymal stromal cells differentiate along adipogenic, osteogenic and chondrogenic lineages (trilineage potential), produce significantly higher levels of cytokines than plastic adherence-mesenchymal stromal cells, and significantly inhibit the proliferation of allogeneic T-lymphocytes in mixed lymphocyte reaction assays. Elevated levels of prostaglandin E2, but not nitric monoxide, mediated the majority of this immunosuppressive effect. In vivo studies showed that CD271-mesenchymal stromal cells promoted significantly greater lymphoid engraftment than did plastic adherence-mesenchymal stromal cells when co-transplanted with CD133 + hematopoietic stem cells at a ratio of 8:1 in immunodeficient NOD/SCID-IL2Rg null mice. They induced a 10.4-fold increase in the number of T cells, a 2.5-fold increase in the number of NK cells, and a 3.6-fold increase in the number of B cells, indicating a major qualitative difference between these two mesenchymal stromal cell populations. ConclusionsOur results indicate that CD271 antigen provides a versatile marker for prospective isolation and expansion of multipotent mesenchymal stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. The co-transplantation of such cells together with hematopoietic stem cells in patients with hematologic malignancies may prove valuable in the prevention of impaired/delayed T-cell recovery and graft-versus-host disease.Key words: T-cell recovery, graft-versus-host disease, MSC.Citation: Kuçi S, Kuçi Z, Kreyenberg H, Deak E, Pütsch K, Huenecke S, Amara C, Koller S, Rettinger E, Grez M, Koehl U, Henschler R, Tonn T, von Laer D, Klingebiel T, and Bader P. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010;95:651-659. doi:10.3324/haematol.2009 This is an open-access paper. © F e r r a t a S t o r t i F o u n d a t i o n CD271 antigen defines a subset of m...

show abstract

Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia

Cited by 34 publications

References 7 publications

Mesenchymal stem cells in tumor development

Mesenchymal stem cells in tumor development

Inflammation and cancer

CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties

Contact Info

Product

Resources

About